UBS Downgrades Ormat Technologies, Stock Slides on Valuation Concerns

What happened

UBS revised its rating and price target on Ormat Technologies on October 1, 2026, causing the stock to decline. The firm's action came as Ormat projected a 2028 revenue run-rate of $1.225 billion to $1.275 billion, which implies only modest growth from the company's FY2026 guidance of $1.11–$1.16 billion. This tepid growth outlook contrasts with the premium valuation highlighted in the DeepValue master report, which noted a P/E of 53.7 and EV/EBITDA of 17.9. The earlier report had already flagged execution risks around storage CODs, Nevada PUC approvals, and tax credit monetization as key catalysts that needed to be resolved to support the stock. The UBS downgrade suggests that sell-side analysts are now questioning whether the AI/data-center geothermal narrative can deliver sufficient revenue growth to justify the price.

Implication

The UBS revision indicates a shift in market sentiment, potentially leading to further multiple compression if Ormat fails to deliver on its near-term catalysts. With the stock still trading around $110–$115 per share, the risk-reward appears balanced at best, as the DeepValue master report's base case implied value was $115, with a bear case of $85. Investors should closely monitor the Nevada PUC decision on the Google/NV Energy geothermal portfolio, expected in the second half of 2026, as a binary event that could either validate or break the AI-geothermal thesis. Storage revenue growth, particularly the Bird Dog project and FY2026 guidance of $95–$110 million, will be critical to demonstrate that the company can diversify beyond geothermal and justify the current multiple. Until these catalysts are resolved, a WAIT posture is appropriate, with a preference for entry points closer to $95 if broader market conditions deteriorate.

Thesis delta

The UBS downgrade does not fundamentally change the investment thesis, which was already cautious due to rich valuation and unresolved near-term catalysts. However, the 2028 revenue run-rate implies slower growth than the market may have anticipated, strengthening the case for a valuation reset. The DeepValue WAIT rating remains intact, with a bias toward the bear scenario if regulatory approvals stall.